Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project

References

• Adrianzén C, Arango‐Dávila C, Araujo DM, Ruíz I, Walton RJ, Dossenbach M, Karagianis J. 2010. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol. 25(6):439–447.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders (DSM-4®). Washington (DC): APA
   Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington (DC): APA
   Google Scholar
• Beckmann B, Hippius H, Rüther E. 1979. Treatment of schizophrenia. Prog Neuro-Psychopharmacol. 3(1–3):47–52.
   Web of Science ®Google Scholar
• Bernagie C, Danckaerts M, Wampers M, De Hert M. 2016. Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs. 30(9):807–818.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones BD. 1979. Early onset of tardive dyskinesia: case report. Am J Psychiatry. 136(10):1323–1324.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Boisvert D, Bradwejn J. 1982. Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J. 126:821–822.
   PubMed Web of Science ®Google Scholar
• Citrome L, Dufresne R, Dyrud JM. 2007. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Mange Care. 12(1):1–12.
   Google Scholar
• Clopper C, Pearson E. 1934. The use of confidence or fiducial limits illustrated in the case of the binominal. Biometrika. 26(4):404–413.
   Google Scholar
• Correll CU, Kane JM, Citrome LL. 2017. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 78(8):1136–1147.
   PubMedGoogle Scholar
• Cloud JL, Zutshi D, Factor SA. 2014. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 11(1):166–176.
   PubMed Web of Science ®Google Scholar
• De Leon J. 2007. The effect of atypical versus typical antipsychotics on tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci. 257(3):169–172.
   PubMed Web of Science ®Google Scholar
• Divac N, Prostran M, Jakovcevski I, Cerovac N. 2014. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014(656370):1–6.
   Web of Science ®Google Scholar
• Dolder C, Lacro J, Dunn L, Jeste D. 2002. Antipsychotic medication adherence: is there a difference between typical and atypical agents? AJP. 159(1):103–108.
   Web of Science ®Google Scholar
• Druschky K, Bleich S, Grohmann R, Engel R, Toto S, Neyazi A, Däubl B, Stübner S. 2020. Severe parkinsonism under treatment with antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 270(1):35–47.
   PubMed Web of Science ®Google Scholar
• Egan MF, Apud J, Wyatt RJ. 1997. Treatment of tardive dyskinesia. Schizophr Bull. 23(4):583–609.
   PubMed Web of Science ®Google Scholar
• Ekbom K, Lindholm H, Ljungberg I. 1972. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 202(2):94–103.
   PubMedGoogle Scholar
• Engel RR, Grohmann R, Rüther E, Hippius H. 2004. Research methods in drug surveillance. Pharmacopsychiatry. 37(1):12–15.
   PubMed Web of Science ®Google Scholar
• Estevez-Fraga C, Zeun P, Moreno JL. 2018. Current methods for the treatment and prevention of drug-induced Parkinsonism and tardive dyskinesia in the elderly. Drugs Aging. 35(11):959–971.
   PubMed Web of Science ®Google Scholar
• Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. 1964. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 40(1):10–26.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Hofer A, Jagsch C, Pirker W, Psota G, Rittmannsberger H, Seppi K. 2016. Antipsychotic-induced tardive syndromes. Neuropsychiatr. 30(3):123–130.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Hasan A, Falkai P, editors. 2019. S3-Leitlinie Schizophrenie [S3 guideline schizophrenia]. Berlin (Germany): Springer. German.
   Google Scholar
• Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. 1990. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 157:585–592.
   PubMed Web of Science ®Google Scholar
• Grohmann R, Engel RR, Rüther E, Hippius H. 2004. The AMSP drug safety program: methods and global results. Pharmacopsychiatry. 37(1):4–11.
   Google Scholar
• Grohmann R, Engel RR, Möller HJ, Rüther E, Van der Velden JW, Stübner S. 2014. Flupentixol use and adverse reactions in comparison with other common first-and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci. 264(2):131–141.
   PubMed Web of Science ®Google Scholar
• Hacke W, Poeck K. 2006. Neurologie [Neurology]. Berlin (Germany): Springer. German.
   Google Scholar
• Hawthorne JM, Caley CF. 2015. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 49(10):1136–1152.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Nishikawa T, Koga I, Uchida Y, Yamawaki S. 1996. Prevalence of and risk factors for respiratory dyskinesia. Clin Neuropharmacol. 19(5):390–398.
   PubMed Web of Science ®Google Scholar
• Hirjak D, Kubera KM, Bienentreu S, Thomann PA, Wolf RC. 2019. Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 1: Dystonia, akathisia und parkinsonism. Nervenarzt. 90(1):1–11.
   PubMed Web of Science ®Google Scholar
• Holloman LC, Marder SR. 1997. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 54(21):2461–2477.
   PubMed Web of Science ®Google Scholar
• Horacek J. 2000. Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry. 33:34–42.
   PubMed Web of Science ®Google Scholar
• Hurwitz N, Wade OL. 1969. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1(5643):531–536.
   PubMed Web of Science ®Google Scholar
• Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jørgensen KN, Melle I, Andreassen OA, Molden E, et al. 2018. Side effect burden of antipsychotic drugs in real life – impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 82:263–271.
   PubMed Web of Science ®Google Scholar
• Jankelowitz SK. 2013. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 9:1371–1380.
   PubMed Web of Science ®Google Scholar
• Janno S, Holi M, Tuisku K, Wahlbeck K. 2004. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 161(1):160–163.
   PubMed Web of Science ®Google Scholar
• Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. 2006. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res. 81(2-3):139–143.
   PubMed Web of Science ®Google Scholar
• Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. 1998. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 121(11):2053–2066.
   PubMed Web of Science ®Google Scholar
• Koek RJ, Pi EH. 1989. Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics. 30(4):359–364.
   PubMed Web of Science ®Google Scholar
• Köhler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. 2000. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 38(11):504–513.
   PubMed Web of Science ®Google Scholar
• Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand S-L, Rochon PA. 2005. Antipsychotic medications and drug‐induced movement disorders other than parkinsonism: a population‐based cohort study in older adults. J Am Geriatr Soc. 53(8):1374–1379.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel R, Li C, Davis JM. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Loughlin AM, Lin N, Abler V, Carroll B. 2019. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PLoS One. 14(6):e0216044.
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. 2002. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 28(1):5–16.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. 2005. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 50(11):703–714.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Ferreri F. 2007. Management of conventional antipsychotic-induced tardive dyskinesia. J Psychiatry Neurosci. 32(1):72.
   PubMed Web of Science ®Google Scholar
• Martino D, Karnik V, Osland S, Barnes TR, Pringsheim TM. 2018. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. 63(11):730–773.
   Web of Science ®Google Scholar
• Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RSE, Rosenheck RA, Stroup TS, et al. 2005. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 80(1):33–43.
   PubMed Web of Science ®Google Scholar
• Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RSE, et al. 2008. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 193(4):279–288.
   PubMed Web of Science ®Google Scholar
• Mörkl S, Seltenreich D, Letmaier M, Bengesser S, Wurm W, Grohmann R, Bleich S, Toto S, Stübner S, Butler MI, et al. 2020. Extrapyramidal reactions following treatment with antidepressants: results of the AMSP multinational drug surveillance programme. World J Biol Psychiatry. 21(4):308–316.
   PubMed Web of Science ®Google Scholar
• Nilanjan CC, Shabina AS, Ritambhara YM, Kamlesh RD. 2017. Severe tardive dystonia on low dose short duration exposure to atypical antipsychotics: factors explored. Indian J Psychol Med. 39(1):96–98.
   PubMedGoogle Scholar
• Peluso MJ, Lewis SW, Barnes TR, Jones PB. 2012. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 200(5):387–392.
   PubMed Web of Science ®Google Scholar
• Pena MS, Yaltho TC, Jankovic J. 2011. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 26(1):147–152.
   PubMed Web of Science ®Google Scholar
• Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. 1997. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 280(1):73–82.
   PubMed Web of Science ®Google Scholar
• Peuskens J. 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 166(6):712–733.
   PubMed Web of Science ®Google Scholar
• Sachdev PS. 2000. The current status of tardive dyskinesia. Aust N Z J Psychiatry. 34(3):355–369.
   PubMed Web of Science ®Google Scholar
• Saifee TA, Edwards MJ. 2011. Tardive movement disorders: a practical approach. Pract Neurol. 11(6):341–348.
   PubMedGoogle Scholar
• Savitt D, Jankovic J. 2018. Tardive syndromes. J Neurol Sci. 389:35–42.
   PubMed Web of Science ®Google Scholar
• Schmauß M, Baumgärtner J, Müller WE. 2019. Weiterbildungs-Curriculum Psychopharmakologie/Psychopharmakotherapie, Folge 9: Antipsychotika [Education curriculum psychopharmacology/psychopharmacotherapy, episode 9: antipsychotics]. Psychopharmakotherapie. 26:282–298. German.
   Google Scholar
• Seeman MV. 2004. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 161(8):1324–1333.
   PubMed Web of Science ®Google Scholar
• Seidl LG, Thornton GF, Cluff LE. 1965. Epidemiological studies of adverse drug reactions. Am J Public Health Nations Health. 55(8):1170–1175.
   PubMed Web of Science ®Google Scholar
• Selfani K, Soland VL, Chouinard S, Huot P. 2017. Movement disorders induced by the "Atypical" Antipsychotic Aripiprazole. Neurologist. 22(1):24–28.
   PubMed Web of Science ®Google Scholar
• Smith JM, Baldessarini RJ. 1980. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 37(12):1368–1373.
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, Correll CU. 2018. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 389:21–27.
   PubMed Web of Science ®Google Scholar
• Stübner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H, Möller HJ, Rüther E. 2000. Pisa-Syndrome (Pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry. 61(8):569–574.
   PubMedGoogle Scholar
• Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, Möller HJ, Hippius H, Rüther E. 2004. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 37(1):54–64.
   Google Scholar
• Stübner S. 2006. Arzneimittelsicherheit: Unerwünschte Wirkungen von Antipsychotika - klinische Daten aus dem multizentrischen Projekt ‘Arzneimittelsicherheit in der Psychiatrie (AMSP)’ [dissertation] [Drug safety: adverse effects of antipsychotics - clinical data from the multicentre project 'Arzneimittelsicherheit in der Psychiatrie (AMSP)’]. Munich (Germany): Ludwig-Maximilians-University.
   Google Scholar
• Stübner S, Grohmann R, Eckermann G, Hiemke C, Lorenzl S. 2018. Psychopharmaka in der Palliativmedizin: Diskussionswürdige Praxis [Psychotropic drugs in palliative care: a practice worthy of discussion]. Dtsch Arztebl. 115(18):A-868/B–738/C-738. German.
   Google Scholar
• Tarsy D. 1983. History and definition of tardive dyskinesia. Clin Neuropharmacol. 6(2):91–99.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Badlessarini RJ, Tarazi FI. 2002. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 16:23–45.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. 2006. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 21(5):589–598.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Lungu C, Baldessarini RJ. 2011. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 100:601–616.
   PubMedGoogle Scholar
• Teo JT, Edwards MJ, Bhatia K. 2012. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 27(10):1205–1215.
   PubMed Web of Science ®Google Scholar
• Van Harten PN. 1997. Acute dystonia. Ned Tijdschr Geneeskd. 141(30):1471–1474.
   PubMedGoogle Scholar
• Vinuela A, Kang UJ. 2014. Reversibility of tardive dyskinesia syndrome. Tremor Other Hyperkinet Mov, 4. 27(4):282.
   Google Scholar
• Vollset SE. 1993. Confidence intervals for a binomial proportion. Stat Med. 12(9):809–824.
   PubMed Web of Science ®Google Scholar
• Waln O, Jankovic J. 2013. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 3(0):03.
   Google Scholar
• Williams R. 2001. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry. 62(4):282–289.
   PubMed Web of Science ®Google Scholar
• Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. 1998. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 155(11):1521–1528.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2016. International statistical classification of diseases and related health problems. 10th ed. https://icd.who.int/browse10/2016/en
   Google Scholar
• Zutshi D, Cloud LJ, Factor SA. 2014. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov. 4(0):266.
   PubMedGoogle Scholar